Five labs fail to replicate therapeutic effects of psilocybin in mice Despite using identical protocols, the group of researchers showed that many oft-reported positive effects of psilocybin were not reproducible. Written byAllison Whitten, PhD

Five labs fail to replicate therapeutic effects of psilocybin in mice Despite using identical protocols, the group of researchers showed that many oft-reported positive effects of psilocybin were not reproducible. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/five-labs-fail-to-replicate-therapeutic-effects-of-psilocybin-in-mice-17659 The field of psychedelic therapeutics is moving fast; there are now hundreds of clinical trials spanning early to late stages, led by small biotechs and Big Pharma companies alike. This Monday, Compass Therapeutics announced they submitted a New Drug Application (NDA) to the FDA for COMP360, a synthetic form of psilocybin, for treatment-resistant depression. Yet, these trials are rapidly progressing against a backdrop of inconsistent results in the foundational science investigating these drugs. Animal behavior experiments do not always show positive effects from psychedelic therapies, and discrepancies can arise from differences in the dose, experimental conditions, and behavioral tests used.